BofA raises Travelers stock price target on strong ROE performance By Investing.com

BofA Securities raised its price target on Travelers to $276 from $257 while keeping an Underperform rating, as the insurer’s first-quarter results were mixed. EPS and revenue beat recent expectations at $7.71 versus $6.97 consensus and $11.92 billion versus $10.75 billion, but BofA cited weaker net written premium growth of -1.7%, catastrophe losses of $761 million versus a $532 million estimate, and a 29% expense ratio. Share buybacks were strong at $1.99 billion, and favorable development of $413 million helped offset some of the underwriting pressure.

Analysis

TRV’s quarter is better read as a quality-of-earnings signal than a clean growth story: buybacks and reserve development are propping up reported returns while top-line momentum remains weak. That combination usually supports the stock in the very short term, but it also raises the probability that future quarters revert toward a lower multiple once reserve releases normalize and catastrophe severity mean-reverts. The key second-order issue is that a carrier trading at a modest headline P/E can still be expensive if normalized ROE compresses by only a few points.

The main competitive implication is not TRV-specific; it is a read-through on the U.S. P&C pricing cycle. If one large multiline insurer is already showing negative written premium growth despite elevated catastrophe pressure, it suggests the market may be moving from hard pricing to selective competition sooner than consensus expects. That tends to favor best-in-class underwriters with superior expense leverage and diversified fee streams, while pressure builds on less disciplined personal/commercial lines writers that need premium growth to offset loss-cost inflation.

Near term, the tradeable catalyst is not the beat itself but what happens if catastrophe activity normalizes and reserve releases fade over the next 1-3 quarters. In that scenario, headline return on equity can compress quickly, and the market typically rerates insurers on normalized earnings power rather than peak-cycle ROE. The contrarian angle is that the stock may actually be supported on any dip because buybacks remain a meaningful bid; that makes outright shorting TRV poor risk/reward unless paired against a higher-quality name or financed with calls.

The bigger market miss is that a strong capital return profile can mask stagnating intrinsic growth. If management keeps repurchasing at a steady pace while underwriting growth is flat, per-share metrics can look resilient for another few quarters even as franchise value erodes. That usually creates a lagged setup: the stock looks cheap until the market decides capital deployment is substituting for organic value creation.

Key Decisions for Investors

• Short-dated underweight TRV versus a higher-quality P&C peer basket for the next 1-2 quarters; use any post-earnings bounce to initiate, targeting 8-12% relative downside if reserve releases normalize.
• If staying involved in TRV, express via put spreads rather than stock short: 3-6 month downside hedge with limited premium outlay, aimed at a re-rating if catastrophe losses remain elevated into the next reporting cycle.
• Pair long a best-in-class multiline insurer against TRV on a relative-value basis, favoring the name with stronger organic premium growth and lower expense ratio; this reduces beta to the sector while isolating underwriting quality dispersion.
• Do not chase the headline buyback yield: wait for a 5-7% pullback or evidence of renewed net written premium growth before adding TRV, since the current support mechanism is capital return rather than accelerating franchise momentum.
• Monitor next-quarter catastrophe and reserve development closely; if favorable development drops materially from this quarter, trim or exit, because that is the fastest path to multiple compression over a 1-2 quarter horizon.